SCHEMBL377390

SCHEMBL377390

COc1cc(OC(C)=O)ccc1O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A6 Q4U2R8 1/20 0.55
SLC22A8 Q8TCC7 1/20 0.55
MEN1 O00255 1/20 0.55
RAB9A P51151 1/20 0.55
KMT2A Q03164 1/20 0.55
KDM4E B2RXH2 1/20 0.54
HTT P42858 1/20 0.53
MAOB P27338 1/20 0.52
MAPT P10636 2/20 0.50
CYP3A4 P08684 2/20 0.50
APP P05067 1/20 0.50
TUBB4A P04350 1/20 0.50
TUBB P07437 1/20 0.50
TUBA3C P0DPH7 1/20 0.50
TUBA1B P68363 1/20 0.50
TUBA4A P68366 1/20 0.50
TUBB4B P68371 1/20 0.50
TUBB3 Q13509 1/20 0.50
TUBB2A Q13885 1/20 0.50
TUBB8 Q3ZCM7 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8765708 0.89 KDM4E (0.62) MEN1RAB9AKMT2AKDM4EHTT
SCHEMBL5575505 0.86 SLC22A6 (0.51) SLC22A6SLC22A8MEN1RAB9AKMT2A
SCHEMBL1097259 0.85 CYP3A4 (0.55) MEN1KMT2AKDM4EHTTMAPT
SCHEMBL6198832 0.85 BACE1 (0.57) SLC22A6SLC22A8MEN1RAB9AKMT2A
SCHEMBL153056 0.85 CA12 (0.59) MEN1KMT2AKDM4EMAPTCYP3A4
SCHEMBL28945284 0.84 MEN1 (0.53) SLC22A6SLC22A8MEN1RAB9AKMT2A
SCHEMBL2729632 0.83 TSHR (0.64) MEN1RAB9AKMT2AKDM4EMAPT
SCHEMBL15388923 0.83 KMT2A (0.49) SLC22A6SLC22A8MEN1RAB9AKMT2A
SCHEMBL28025904 0.82 ALDH1A1 (0.54) SLC22A6SLC22A8MEN1RAB9AKMT2A
SCHEMBL26009120 0.81 ACHE (0.57) MEN1KMT2AKDM4EMAPTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140356540-A1 PROCESS FOR CURING SURFACE-COATING COMPOSITIONS CYTEC AUSTRIA GMBH (AT) 2014-12-04 US claimed
EP-1534693-A2 1, 3-DIAMINO-2-HYDROXYPROPANE PRODRUG DERIVATIVES Elan Pharmaceuticals, Inc. (US) 2005-06-01 EP claimed
WO-2004022523-A2 1, 3-DIAMINO-2-HYDROXYPROPANE PRODRUG DERIVATIVES ELAN PHARMACEUTICALS, INC. (US) 2004-03-18 WO claimed
EP-4467163-A2 SELF INDICATING ANTIMICROBIAL CHEMISTRY Ecolab USA Inc. (US) 2024-11-27 EP disclosed
EP-4420517-A2 SELF INDICATING ANTIMICROBIAL CHEMISTRY Ecolab USA Inc. (US) 2024-08-28 EP disclosed
EP-3904526-B1 SELF INDICATING ANTIMICROBIAL CHEMISTRY ECOLAB USA INC (US) 2024-07-10 EP disclosed
US-20230210808-A1 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS CYMABAY THERAPEUTICS, INC. 2023-07-06 US disclosed
US-11576378-B2 Self indicating antimicrobial chemistry ECOLAB USA INC. (US) 2023-02-14 US disclosed
EP-3904526-A1 SELF INDICATING ANTIMICROBIAL CHEMISTRY Ecolab USA Inc. (US) 2021-11-03 EP disclosed
EP-3346836-B1 SELF INDICATING ANTIMICROBIAL CHEMISTRY ECOLAB USA INC (US) 2021-07-21 EP disclosed
CN-108473484-B Compounds useful as TRPM8 modulators 弗门尼舍公司 2021-06-29 CN disclosed
US-20040122100-A1 Remedies for post-traumatic stress disorder KYOTO UNIVERSITY (JP) 2004-06-24 US disclosed
EP-1374899-A1 REMEDIES FOR POST-TRAUMATIC STRESS DISORDER ONO PHARMACEUTICAL CO., LTD. (JP) 2004-01-02 EP disclosed
WO-2003099793-A1 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-04 WO disclosed
EP-0758013-B1 Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display NIPPON OIL CO LTD (JP) 2000-10-11 EP disclosed
CN-1207173-A Method of measurement of material and testpiece KYOTO DAIICHI KAGAKU KK (JP) 1999-02-03 CN disclosed
US-5855971-A Liquid crystalline optical film, compensating film for liquid crystal display comprising the liquid crystalline optical film, and liquid crystal display having the compensating film NIPPON OIL COMPANY, LIMITED (JP) 1999-01-05 US disclosed
EP-0758013-A1 Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display NIPPON OIL COMPANY, LIMITED (JP) 1997-02-12 EP disclosed
US-5401604-A Reaction product of polyepoxide, aromatic acid with phenolic hydroxy group, aromatic acid, quinone diazide with sulfonyl group, photoresists NIPPON PAINT CO., LTD. (JP) 1995-03-28 US disclosed
WO-1990014083-A1 COMPOSITION AND METHOD FOR NEURAL DESENSITIZATION AFFERON CORPORATION (US) 1990-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210808-A1 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS PPARA, PPARG, PPARD SLC22A6 1444/4885SLC22A8 1580/4885MEN1 4877/4885
US-11576378-B2 Self indicating antimicrobial chemistry HPD, HAO2, OAT SLC22A6 705/4885SLC22A8 390/4885MEN1 4350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.